Financial Performance - Total Revenues for the fiscal year 2024.4-2025.3 reached 2,874,821 million yen[5], a slight increase from 2,814,361 million yen in the previous fiscal year[5] - Net Income Attributable to ORIX Corporation Shareholders for the fiscal year 2024.4-2025.3 was 351,630 million yen[5], compared to 346,132 million yen in the previous fiscal year[5] - Return on Equity (ROE) for the quarter 2025.4-6 increased to 10.4%[5] from 9.2% in the same quarter of the previous year[5] - Return on Assets (ROA) for the quarter 2025.4-6 increased to 2.53%[5] from 2.19% in the same quarter of the previous year[5] Segment Performance - Total segment profits reached 544,668 million yen[7], with an adjustment of -64,205 million yen[7] leading to an income before income taxes of 480,463 million yen[7] - Corporate Financial Services and Maintenance Leasing reported segment profits of 90,329 million yen[7] and segment assets of 1,884,565 million yen[7] - Real Estate segment profits were 70,541 million yen[7] with segment assets of 1,158,293 million yen[7], showing a segment asset ROA of 4.26%[7] - PE Investment and Concession segment profits amounted to 98,872 million yen[7] with segment assets of 1,022,944 million yen[7], resulting in a segment asset ROA of 6.96%[7] - Insurance segment profits were 74,399 million yen[7] with segment assets of 3,009,234 million yen[7], and a segment asset ROA of 1.80%[7] Asset and Funding - Total Assets reached 16,866,251 million yen[5], with Total Liabilities at 12,691,036 million yen[5] and Total ORIX Corporation Shareholders' Equity at 4,089,782 million yen[5] - The Shareholders' Equity Ratio stood at 24.2%[6], and the Debt-to-Equity Ratio was 2.1 times[6] - The company maintains strong liquidity, with a liquidity coverage ratio of 2,086%[86]

Financial Performance - Q1 FY2025 Results (Continuing Operations) - Sales increased by 563 billion yen (+2%) year-on-year to 26216 billion yen, with an approximately 8% increase on a constant currency basis[6, 8] - Operating income increased by 908 billion yen (+36%) year-on-year to 3400 billion yen, with operating income margin at 130%, a 33 percentage point increase[6] - Net income attributable to Sony Group Corporation's stockholders increased by 489 billion yen (+23%) to 2590 billion yen[6] Segment Performance - Q1 FY2025 - Game & Network Services (G&NS) sales increased by 716 billion yen (+8%) to 9365 billion yen, and operating income increased by 827 billion yen (+127%) to 1480 billion yen[9, 22] - Music sales increased by 233 billion yen (+5%) to 4653 billion yen, and operating income increased by 69 billion yen (+8%) to 928 billion yen[9, 26] - Pictures sales decreased by 102 billion yen (-3%) to 3271 billion yen, but operating income increased by 74 billion yen (+65%) [9, 30] - Entertainment, Technology & Services (ET&S) sales decreased by 667 billion yen (-11%) to 5343 billion yen, and operating income decreased by 209 billion yen (-33%) to 431 billion yen[9, 39] - Imaging & Sensing Solutions (I&SS) sales increased by 547 billion yen (+15%) to 4082 billion yen, and operating income increased by 176 billion yen (+48%) to 543 billion yen[9, 44, 47] FY2025 Forecast (Continuing Operations) - Sales forecast remains unchanged at 117 trillion yen[10, 16] - Operating income forecast increased by 50 billion yen (+4%) to 133 trillion yen after considering a 70 billion yen estimated tariff impact[10, 11, 16] - Net income attributable to Sony Group Corporation's stockholders forecast increased by 40 billion yen (+4%) to 970 billion yen[10, 15] Spin-off of Financial Services Business - Sony plans to execute a partial spin-off of Sony Financial Group Inc (SFGI) in October 2025, classifying the Financial Services business as a discontinued operation from Q1 FY25[3, 4] - A considerable one-time loss will be recorded in the consolidated statements of income at the time of the execution of the Spin-off, but there will be no impact on operating income and net income from continuing operations[52]

FY2026 Forecast Revision - Toyota revised its FY2026 operating income forecast downward by 06 trillion yen, from 38 trillion yen to 32 trillion yen [5] - The impact of US tariffs is estimated to be 14 trillion yen, a downward revision from the previous forecast of 12 trillion yen [5] - Consolidated vehicle sales forecasts remain unchanged at 98 million units [35] FY2026 First Quarter Performance - Operating income for the first quarter of FY2026 was 11661 billion yen, a decrease of 1423 billion yen year-on-year [15] - Net income attributable to Toyota Motor Corporation decreased by 4920 billion yen to 8413 billion yen [15] - Total retail vehicle sales increased by 73% year-on-year, reaching 2829 thousand units [11] Sales Performance - Toyota and Lexus vehicle sales increased by 61% year-on-year, reaching 2643 thousand units [11] - Electrified vehicle sales increased by 171% year-on-year, reaching 1259 thousand units, representing 476% of total retail vehicle sales [11] - Consolidated vehicle sales increased by 71% year-on-year to 2411 thousand units [13] Financial Analysis - Sales revenues increased by 4154 billion yen to 122533 billion yen [15] - The operating income margin decreased from 111% to 95% [15] - The analysis of consolidated operating income indicates a negative impact of 4500 billion yen due to tariffs [19] Regional Performance - In North America, vehicle sales increased by 142% [22] - In Asia, vehicle sales increased by 127% [22] - China Business operating income of consolidated subsidiaries increased by 104 billion yen [27] Financial Forecasts - Sales Revenues are forecasted to be 485 trillion yen [38] - Net Income Attributable to Toyota Motor Corporation is forecasted to be 266 trillion yen [38]

Financial Performance - Q2 2025 - Net revenue increased by 80% to RMB559 million (or $78 million) compared to Q2 2024[20] - Gross profit increased by 102% to RMB283 million (or $40 million) compared to Q2 2024[20] - Revenues from Overseas Study Counselling, Research-based Learning and Other Educational Services increased by 542% compared to Q2 2024[12] - Net loss attributable to ACG was RMB108 million (or $15 million) in Q2 2025, compared to RMB168 million in Q2 2024[20] Financial Performance - H1 2025 - Net revenue increased by 118% to RMB1117 million (or $156 million) compared to H1 2024[21] - Gross profit increased by 128% to RMB537 million (or $75 million) compared to H1 2024[21] - Revenues from Overseas Study Counselling, Research-based Learning and Other Educational Services increased by 408% compared to H1 2024[15] - Net loss attributable to ACG was RMB241 million (or $34 million) in H1 2025, compared to RMB347 million in H1 2024[21] Operational Highlights - Q2 2025 - Portfolio Training Services accounted for 680% of total revenues[18] - Project-based programs accounted for 767% of total credit hours delivered within portfolio training services, compared to 612% in Q2 2024[18] - Research-Based Learning Services comprised 320% of Q2 2025 total net revenues, compared to 224% in Q2 2024[18] FY 2025 Guidance - Revenue is projected to grow by approximately 3% to 5% versus FY 2024, reaching RMB276 million – RMB281 million[33]

Financial Performance - Group underlying NPAT increased by 9.2% to $131 million compared to $120 million in 1H 24[5, 27] - Underlying EPS increased by 18.2% to 5.2 cents per share[6, 27] - Controllable costs improved by 4.4% to $303 million[5, 27, 90] - Cost to income ratio improved by 2.9 percentage points to 59.4%[6, 27] Assets Under Management (AUM) - Total AUM increased by 3.7% since FY 24 to $153.9 billion[6, 30] - Platforms AUM grew by 4.3% to $83.2 billion[32] - Superannuation & Investments AUM grew by 2.8% to $58.5 billion[32] - New Zealand Wealth Management AUM increased by 3.6% to $12.2 billion[32] Business Unit Performance - Platforms underlying NPAT increased by 7.4% to $58 million[33, 37] - Superannuation & Investments underlying NPAT remained stable at $34 million[33, 48] - AMP Bank underlying NPAT increased by 2.9% to $36 million[33, 61] - New Zealand Wealth Management underlying NPAT increased by 11.8% to $19 million[33, 74] - Group underlying NPAT showed a decrease of 20.0% to -$16 million[33, 77] AMP Bank - Residential mortgage book grew by 2.8% to $23.326 billion[61] - Net interest margin (NIM) increased by 2 basis points to 1.30%[61] - Transactional balances for 'AMP Bank GO' reached $123 million[21]

Financial Performance & Growth - The company reported a 39% profit growth [30] - Underlying EBITDA for 1H26 is projected to be $14 million to $16 million [30, 56] - Underlying EBITDA increased by 20% to $23.5 million from $19.5 million [43] - Underlying EBITDAR Per Care Bed increased by 13% to $27.9K from $24.7K [45] - Total FY25 cash dividend was 1.45cps, compared to 0.70cps in FY24 [45] Expansion & Acquisitions - Acquired St Allisa, a 109-bed care home, through a leaseback arrangement [24, 27, 30] - Acquired 51% of Cibus Catering Limited, resulting in a $4.1 million revenue uplift [30] - Pursuing capital-light expansion focused on new-build 100-bed care homes leased from private investors [28] Operational Efficiency & Staffing - Company-wide staff turnover decreased by 30% year-on-year, reaching a record low [48] - 86% of care homes audited in FY25 received 4-Year Certification [49] - Average occupancy is trending upwards, reaching approximately 95% [50] - The company acquired 920,000 shares for $280,000, with an average buyback price of 30.4cps [39, 40]

Dimerix Overview - Dimerix is developing DMX-200, a lead drug candidate in Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS)[14] - FSGS is a rare kidney disease with no approved treatments, leading to irreversible kidney damage, dialysis, transplant, or death[14] - Dimerix has secured orphan drug designation for DMX-200, providing regulatory, marketing exclusivity, and pricing benefits in key territories[14] - Dimerix has licensing partners across key territories for DMX-200[14] Financial Achievements and Partnerships - Dimerix has received over AU$65 million in total payments to date[14,54] - Licensing deals are collectively valued up to approximately AU$1.4 billion in total upfront and potential milestone fees plus royalties[14,53] - A 3rd development and license agreement for DMX-200 in Japan is valued up to ¥10.5 billion (~AU$107 million) in upfront/milestones, plus royalties[17] - A 4th license agreement for DMX-200 in the United States is valued up to US$590 million (~AU$940 million) in upfront/milestones, plus royalties[17] Clinical Trial and Regulatory Progress - The FDA confirmed proteinuria as an acceptable endpoint for full marketing approval in the US[17] - The ACTION3 study has enrolled 225 patients, with 52 patients enrolled in the Open Label Extension Study as of August 5, 2025[33] - The Phase 3 trial aims to recruit a total of approximately 286 patients[33] - Dimerix held a positive Type C meeting with the FDA in March 2025 regarding proteinuria trial endpoints for full approval and potential accelerated approval for DMX-200[41] Market Opportunity - The estimated global incidence of FSGS is over 200,000 per year[61] - The estimated incidence of FSGS per year across all Dimerix licensed territories is approximately 50,071[61]

Market Drivers & Trends - Drone warfare is driving an urgent market need for counter-drone solutions[2,7] - The rapid rise of drones has changed the battlefield, with offense currently in the ascendant[13] - Effective counter-drone strategies require a layered response, with EOS products playing a complementary role[14] - High Energy Laser Weapons (HELW) meet many requirements for drone swarm defense, offering accuracy, speed, economy, and coverage[19] EOS's High Energy Laser Weapon (HELW) - EOS has signed a €71.4 million (~A$125 million) contract with a European customer for a 100-kW high energy laser system[4] - The 100kW system contract includes container module, laser modules, beam director and management system, system integration, documentation and support, power and cooling[36] - The system will be delivered over three years from EOS' facilities in Singapore[4] - EOS' main commercial focus is presently the 30-150kW power class of HELW[19] - Key technology is wholly owned by EOS, ITAR-free (no US content)[29] Competitive Landscape & Growth - The US market is dominated by large local primes, with >US$1 billion spend per annum on laser weapons[22] - EOS sees well-funded and growing customer interest in the European, Middle East & APAC markets for non-ITAR/non-US products[22] - EOS believes it has significant competitive advantages in laser weapons due to its expertise across multiple technically complex subsystems[22]

Market Opportunity and Unmet Needs - Achieve Life Sciences has a unique opportunity to address a market of up to 50 million Americans who use tobacco with Cytisinicline[6] - Nicotine dependence is a public health crisis costing billions of dollars[6] and there are ~29 million US smokers with few treatment options[12] - Approximately 60% of adult e-cigarette users want to quit[14], with ~17 million US adults reporting e-cigarette use[16] - An estimated $11 Billion Rx opportunity exists in the market[46] Cytisinicline's Potential and Clinical Data - Cytisinicline is presented as the first potential new nicotine dependence treatment option in nearly 20 years[6, 18] - ORCA-2 and ORCA-3 trials showed strong results in smoking cessation, demonstrating efficacy, tolerability, and craving reduction[22] - In the 12-week Cytisinicline Treatment, the quit rate is 32.6% compared to 7% in the placebo group[23] - In the 6-week Cytisinicline Treatment, the quit rate is 25.3% compared to 4.4% in the placebo group[23] - Phase 2 ORCA-V1 trial showed a 2.6x (p=0.035) increased likelihood of quitting vaping with cytisinicline[39] Commercialization Strategy - The company anticipates filing a Smoking cessation NDA with launch expected in 2H26[6] - A focused launch strategy will leverage innovative, data-driven solutions to drive adoption and future growth[7] - The company will focus on high-volume prescribers and engaged quitters[48] - The company will target the varenicline market share, which peaked at ~2.8M Rx (75% in U S market - $800M)[51]

For personal use only 2025 AUSTRALIAN RICE CONFERENCE Shaping the future Paul Serra SunRice Group CEO August 2025 2 0 2 5 A U S T R A L I A N R I C E C O N F E R E N C E Important notice & disclaimer This presentation has been prepared by Ricegrowers Limited (SunRice) and provides summary information only. SunRice has prepared this presentation in good faith believing the statements made in it to be true as at the date of the presentation. SunRice is not otherwise warranting the accuracy of the information ...